Malvern Discussion of Analytical Toolkit for Biopharmaceutical Applications is Now Available Online
Product News Apr 12, 2013
A recent Malvern Instruments sponsored webinar, presented by specialists from the company, examined the need for specific analytical tools for biopharmaceutical applications.
The recording of the live event, which attracted more than 600 registrants, is now available to view online at http://bit.ly/MALOTACB.
In the presentation, Mark Pothecary and Paul Clarke, Product Manager and Product Group Manager respectively for Nanoparticle and Molecular Characterization at Malvern Instruments, discuss a variety of the analytical technologies that are available for the growing biopharmaceutical industry.
They provide fresh insights into the use of a number of well-established characterization techniques, including light scattering and size exclusion chromatography (GPC/SEC) and illustrate the use of these techniques in combination, showing how they can provide a wide range of complementary information useful to protein scientists.
The continued shift within the industry towards biopharmaceuticals has resulted in the need for analytical instrumentation that can quickly deliver compelling solutions to meet rapidly evolving analytical and regulatory challenges.
In particular the move towards drugs using biomolecules as the active has stimulated advances in new analytical procedures. As well as traditional techniques, such as GPC/SEC and dynamic light scattering (DLS), which can be performed separately or in combination (SEC-DLS), new technologies including microrheology and resonant mass measurement are rapidly becoming essential components of the analytical toolkit.
Within Malvern Instruments, the company’s global Bioscience Development Initiative recognizes the unprecedented pace of development in biopharmaceuticals and the onus this places on analytical instrumentation companies to quickly deliver solutions to a host of rapidly evolving analytical and regulatory challenges.
Malvern’s Bioscience Development Initiative is focused specifically on the requirements of the biopharmaceutical sector, most notably the biochemical and biophysical characterization needs relating to formulation and product development.